Alzheimer’s Risk, Biomarkers & Cognitive Testing

Alzheimer’s disease does not begin with a single memory lapse, and no single test can tell us everything about a person’s cognitive future.

Today, however, we have better tools than ever for looking at cognitive function, genetic risk, amyloid and tau biology, and other factors that may contribute to neurodegenerative disease. Used thoughtfully, these tools can help establish a baseline, identify changes earlier, clarify what may be driving symptoms, and guide more personalized prevention and treatment strategies.

What You’ll Learn

  • How Alzheimer’s risk differs from an Alzheimer’s diagnosis

  • What APOE genetics can and cannot tell us

  • How cognitive testing helps establish a baseline and track change

  • What amyloid, tau, and newer blood biomarkers measure

  • How Crossroads uses cognitive testing as part of a broader brain-health assessment

Alzheimer’s Risk Is Not the Same as Alzheimer’s Disease

Alzheimer’s disease is associated with characteristic changes in the brain, including abnormal accumulation of beta-amyloid and tau proteins. These changes can begin years before dementia becomes clinically apparent. But biology is only part of the story.

A person’s likelihood of developing cognitive impairment reflects the interaction of many factors, including:

  • Age

  • Genetics

  • Vascular health

  • Blood pressure

  • Metabolic health

  • Sleep

  • Physical activity

  • Nutrition

  • Hearing

  • Head injury history

  • Smoking

  • Social and cognitive engagement

  • Other neurological or medical conditions

This means that being at increased risk does not mean that cognitive decline is inevitable. It also means that brain-health assessment should not focus on one biomarker while ignoring the rest of the person.

APOE: A Risk Gene, Not a Diagnosis

The APOE gene helps regulate lipid transport and has an important relationship with Alzheimer’s disease risk.

Everyone inherits one APOE variant from each parent. The three major forms are commonly referred to as APOE2, APOE3, and APOE4.

APOE4 is associated with increased risk of late-onset Alzheimer’s disease. Having one copy increases risk, while having two copies generally increases risk further.

But APOE4 is not deterministic.

Many people with APOE4 never develop Alzheimer’s disease, and many people who develop Alzheimer’s do not carry APOE4.

This distinction is important because genetic information can easily be misunderstood. APOE testing may be useful in selected situations, particularly when it will meaningfully influence prevention strategies, diagnostic interpretation, or treatment decisions. But it should be interpreted alongside the rest of the clinical picture rather than used as a stand-alone prediction of future dementia.

Why Cognitive Testing Matters

People often notice subtle changes in memory or mental sharpness before those changes are obvious during a routine medical visit.

At the same time, subjective concerns do not always mean that neurodegenerative disease is present. Sleep deprivation, depression, anxiety, medications, pain, hormonal changes, metabolic dysfunction, and many other factors can influence cognition.

This is where objective cognitive testing can be useful. Rather than simply asking, “Do you feel your memory is worse?”, cognitive testing allows us to measure specific domains of brain function.

Depending on the test, these may include:

  • Memory

  • Attention

  • Processing speed

  • Executive function

  • Reasoning

  • Reaction time

  • Visual processing

A single score is less informative than a pattern.

For many people, one of the greatest benefits of cognitive testing is simply establishing a baseline. If testing is repeated later, we can look for meaningful change rather than relying only on memory of how someone seemed several years earlier.

Screening, Assessment, and Diagnosis Are Different

Cognitive testing can serve different purposes. A brief screening test may identify whether additional evaluation is needed. A more detailed computerized assessment can characterize strengths and weaknesses across several cognitive domains and help establish a baseline.

A full neuropsychological evaluation goes considerably deeper and is often appropriate when there is significant concern about cognitive impairment, diagnostic uncertainty, or a need to understand how cognitive changes are affecting daily function. These tools complement one another rather than compete with one another. No computerized test should be used by itself to diagnose Alzheimer’s disease.

Amyloid and Tau: Looking at Alzheimer’s Biology

For many years, confirmation of Alzheimer-related amyloid and tau pathology required specialized testing such as:

  • Amyloid PET imaging

  • Tau PET imaging

  • Cerebrospinal-fluid testing

These remain important tools, but blood-based biomarkers are rapidly changing the field. Researchers can now measure proteins in the blood that correlate with Alzheimer-related brain pathology.

Particularly important markers include:

  • Phosphorylated tau, especially p-tau217

  • p-tau181

  • Amyloid-beta ratios, such as Aβ42/Aβ40

  • GFAP, a marker related to astrocyte activity

  • Neurofilament light chain, or NfL, a more general marker of neuronal injury

Among these, plasma p-tau217 has emerged as one of the strongest-performing blood biomarkers for identifying Alzheimer-related pathology. A large 2025 systematic review and meta-analysis found p-tau217 had the best diagnostic performance among the blood phosphorylated-tau markers evaluated.

Blood Testing Is Changing Alzheimer’s Evaluation

Blood biomarkers are no longer purely research tools.

In 2025, the FDA cleared the first blood-based Alzheimer’s test designed to help identify amyloid pathology in symptomatic adults. Additional blood tests have since received clearance for specific diagnostic uses, including a primary-care test designed to help rule out Alzheimer-related amyloid pathology in appropriate patients with cognitive concerns. This is a major change.

Historically, patients often had to undergo an amyloid PET scan or lumbar puncture before biological Alzheimer’s pathology could be confirmed. Blood testing may make this process more accessible and allow clinicians to identify which patients need additional specialized evaluation.

Not All Alzheimer’s Blood Tests Are the Same

This is an important point. A test marketed as an “Alzheimer’s blood test” is not automatically equivalent to another test. Different assays measure different markers, use different laboratory methods, and have different levels of sensitivity and specificity.

The Alzheimer’s Association’s current clinical guideline recommends that blood biomarkers be used within a structured diagnostic evaluation, particularly in people who already have objective cognitive impairment. Depending on the accuracy of the assay, a blood test may be used either as a triage tool or, in some circumstances, as a confirmatory test.

The guideline also emphasizes that testing should not occur in isolation from a clinical evaluation.

What Does a Positive Alzheimer’s Biomarker Mean?

A positive biomarker suggests that Alzheimer-related biological changes are present.

It does not necessarily tell us:

  • How quickly symptoms will progress

  • When dementia will develop

  • How severe future impairment will be

  • Whether Alzheimer’s pathology is the only reason for current cognitive symptoms

Mixed pathology becomes increasingly common with age.

For example, someone may have amyloid pathology along with small-vessel disease, sleep apnea, metabolic dysfunction, medication effects, or another neurodegenerative process.

This is why biomarker testing should add to a broader assessment rather than replace one.

What About Testing People Without Symptoms?

The ability to measure Alzheimer-related biology before symptoms appear creates obvious interest in screening.

But testing cognitively healthy people raises different questions from evaluating someone who already has objective cognitive impairment.

At present, current clinical guidelines for blood biomarkers are primarily focused on people with cognitive impairment undergoing diagnostic evaluation, not broad population screening of healthy adults.

That does not mean pre-symptomatic testing will never become useful.

As prevention research, risk prediction, and disease-modifying therapies evolve, the role of biomarkers before symptoms develop will likely change as well.

For now, testing should be guided by the reason for testing, the quality of the assay, the person’s clinical history, and what will actually be done with the result.

Biomarkers and Disease-Modifying Treatment

The arrival of therapies that target amyloid has made biological confirmation of Alzheimer’s disease increasingly important.

These medications are not appropriate for everyone, and treatment decisions require careful evaluation of disease stage, imaging, biomarkers, genetic factors, potential risks, and other clinical considerations.

Blood biomarkers may increasingly help identify which patients should proceed to more specialized testing or treatment evaluation.

This is one reason the rapid development of blood-based biomarkers is so clinically important. They are not simply another way to estimate risk. They are increasingly becoming part of real diagnostic and treatment pathways.

Creyos and ViewMind at Crossroads

At Crossroads, cognitive testing is used to provide objective information about how the brain is functioning now and to establish a baseline that can be followed over time. Neither tool diagnoses Alzheimer’s disease on its own. Their value lies in adding objective measurements to the broader picture.

Creyos

Creyos uses computerized cognitive tasks to assess domains such as memory, attention, reasoning, and processing speed. It can help identify patterns that may not be obvious during a routine office visit and provides a practical way to follow cognitive performance over time.

ViewMind

ViewMind uses visual tasks and eye-tracking technology to evaluate aspects of cognitive processing. Eye movements can provide information about how the brain processes visual and cognitive information, adding another dimension to traditional cognitive assessment.

Putting the Pieces Together

The most useful brain-health assessment is rarely based on one test.

Depending on the person, it may include:

  • Cognitive testing

  • Medical and neurological history

  • Family history

  • APOE or other genetic information

  • Blood pressure and vascular assessment

  • Glucose and insulin regulation

  • Lipids and ApoB

  • Sleep quality and evaluation for sleep apnea

  • Nutritional status

  • Medication review

  • Mood and stress

  • Hearing

  • Brain imaging

  • Alzheimer-related blood biomarkers

  • PET or cerebrospinal-fluid testing when appropriate

The goal is not to accumulate as many tests as possible. It is to determine which information will help answer a meaningful clinical question.

From Risk Assessment to Action

Testing is most valuable when it changes what we do.

If cognitive testing identifies a decline, that may prompt more detailed evaluation.

If vascular or metabolic risks are present, they can be addressed.

If nutritional deficiencies, sleep disorders, hearing loss, medication effects, or other contributors are identified, those can become treatment targets.

If Alzheimer-related biomarkers are appropriate and positive, they can help clarify diagnosis and potentially guide referral for disease-modifying treatment.

If testing is reassuring, it can also establish a valuable baseline for future comparison.

This is the central idea behind a precision approach to brain health: measure what matters, interpret it in context, and use the information to guide the next step.

Brain Health Assessment at Crossroads

The Crossroads Brain Health Program combines objective cognitive testing with a broader evaluation of modifiable brain-health factors.

Depending on the individual, this may include Creyos or ViewMind cognitive assessment, vascular and metabolic evaluation, nutrition, sleep, exercise, targeted supplementation, and other brain-health strategies.

When symptoms, cognitive testing, history, or other findings raise concern for neurodegenerative disease, additional biomarker testing, imaging, or specialty neurological evaluation may also be appropriate.

The goal is not simply to identify disease.

It is to understand the individual’s cognitive function and risk profile as clearly as possible so that prevention, monitoring, and treatment can be more personalized.

Related Reading

Brain Health & Cognitive Aging
Return to our overview of vascular health, metabolism, nutrition, sleep, lifestyle, and emerging strategies for maintaining cognitive health.

Previous
Previous

Using a Continuous Glucose Monitor to Understand Your Metabolism

Next
Next

The Sweet Truth About Sugar Substitutes: Are They Really Better Than Sugar?